Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EHRA 24: A Substudy of NOAH-AFNET 6
Author(s): Julius Nikorowitsch Added: 1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more

Electrophysiology & Arrhythmia
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 2 years ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more

Anticoagulation

Electrophysiology & Arrhythmia
AHA 24: The OPTION Trial
Author(s): Oussama M Wazni Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation.Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298).OPTION is a prospective, multi-center, multi… View more

Anticoagulation

Electrophysiology & Arrhythmia
TCT 25: Short-Term Anticoagulation Vs DAPT for Preventing Device Thrombosis Following LAAC
Author(s): Josep Rodés-Cabau Added: 5 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more

Anticoagulation

Imaging & Diagnostics
SOUL: Oral Semaglutide Aids CV Risk in T2D
Added: 2 weeks ago Source:  Radcliffe CVRM
Individuals with type 2 diabetes (T2D) face a high risk of atherosclerotic cardiovascular disease (ASCVD). The SOUL trial (NCT03914326) previously demonstrated that oral semaglutide reduced major adverse cardiovascular events (MACE).² A new post hoc secondary analysis of this trial now provides insight into the mechanisms behind this benefit, detailing the drug's association with changes in key… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
LAAC Not Non-Inferior to Medical Care in High-Risk AF
Added: 2 weeks ago Source:  Interventional Cardiology Review Journal
For patients with atrial fibrillation (AF) at high risk for both stroke and bleeding, catheter-based left atrial appendage closure (LAAC) was not found to be non-inferior to physician-directed best medical care, according to the results of the CLOSURE-AF trial.¹MethodologyThe multicentre, randomised CLOSURE-AF trial was conducted in Germany to assess the effectiveness of LAAC compared with best… View more

Intervention

Prevention & Chronic Conditions
Oral Orforglipron Superior to Semaglutide for T2D Control
Added: 1 month ago Source:  Radcliffe CVRM
A new study has found that the novel oral GLP-1 receptor agonist, orforglipron, demonstrated superior glycaemic control compared to oral semaglutide in adults with type 2 diabetes (T2D). The findings come from the ACHIEVE-3 trial, a phase 3 study published in The Lancet.¹Mechanism of ActionOrforglipron is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-daily oral… View more

Cardiovascular Renal Metabolic
MI and Non-obstructive Coronary Arteries
Author(s): Yetunde A Fatade , Noah A Newman , Nidhi H Patel , et al Added: 1 year ago

Prevention & Chronic Conditions

MI/ACS
NOAC Monotherapy Noninferior to Combo Therapy Post-DES
Added: 1 month ago Source:  Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,… View more

Anticoagulation

Electrophysiology & Arrhythmia